A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: Results of the P.R.I.N.C.E. study

Journal of the American College of Cardiology

Volumn 33, Issue 2, 1999, Pages 403-411

  Stevens, Melissa A ^a   McCullough, Peter A ^a,b   Tobin, Kenneth J ^a   Speck, John P ^a   Westveer, Douglas C ^a   Guido Allen, Debra A ^a   Timmis, Gerald C ^a   O'Neill, William W ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DIATRIZOATE; DOPAMINE; FUROSEMIDE; INFUSION FLUID; MANNITOL; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTRACORONARY INFUSION; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; URINE FLOW RATE;

AGED; CARDIOTONIC AGENTS; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CREATININE; DIURESIS; DIURETICS; DOPAMINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FUROSEMIDE; HUMANS; ISOTONIC SOLUTIONS; KIDNEY DISEASES; MALE; MANNITOL; PLASMA SUBSTITUTES; PROSPECTIVE STUDIES; PULMONARY WEDGE PRESSURE; REHYDRATION SOLUTIONS; RISK FACTORS; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0033081743     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00574-9     Document Type: Article

References (23)

1. Hou S.H., Bushinsky D.A., Wish J.B., Cohen J.J., Harrington J.T. Hospital-acquired renal insufficiency a prospective study. Am J Med. 74:1983;243-248.
2. McCullough P.A., Wolyn R., Rocher L.L., Levin R.N., O'Neill W.W. Acute renal failure after coronary intervention incidence, risk factors, and relationship to mortality. Am J Med. 103:1997;368-375.
3. Chertow G.M. On the design and analysis of multicenter trials in acute renal failure. Am J Kidney Dis. 30:1997;S96-S101.
4. Chertow G.M., Lazarus J.M., Christiansen C.L., et al. Preoperative renal risk stratification. Circulation. 95:1997;878-884.
5. Solomon R., Werner C., Mann D., D'Elia J., Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 331:1994;1416-1420.
6. Anto H.R., Chou S.Y., Porush J.G., Shapiro W.B. Infusion intravenous pyelography and renal function effect of hypertonic mannitol in patients with chronic renal insufficiency. Arch Intern Med. 141:1981;1652-1656.
7. Seyss C., Foote E.F. Calcium-channel blockers for prophylaxis of radiocontrast-associated nephrotoxicity. Ann Pharmacother. 29:1995;187-188.
8. Weinstein J.M., Heyman S., Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron. 62:1992;413-415.
9. Weisberg L.S., Kurnik P.B., Kurnik B.R. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 45:1994;259-265.
10. Allgren R.L., Marbury T.C., Rahman S.N., et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med. 336:1997;828-834.
11. Denton M.D., Chertow G.M., Brady H.R. "Renal-dose" dopamine for the treatment of acute renal failure scientific rationale, experimental studies and clinical trials. Kidney Int. 50:1996;4-14.
12. Carcoana O.V., Hines R.L. Is renal dose dopamine protective or therapeutic? Yes. Crit Care Clin. 12:1996;677-685.
13. Beroniade VC. Prevention of acute renal failure secondary to radiocontrast agents. In: Abstracts of the 8th International Congress of Nephrology, Athens, June 7-12, 1981 [abstract 1981]. Basel, Switzerland: Karger, 1881:380.
14. Old C.W., Durate C.M., Lahrner L.M., Henry A.R., Sinnott R.C. A prospective evaluation of mannitol in the prevention of radiocontrast acute renal failure. [abstract] Clin Res. 29:1981;470A.
15. Cochran S.T., Wong W.S., Roe D.J. Predicting angiography-induced acute renal function impairment clinical risk model. Am J Roentgenol. 141:1983;1027-1033.
16. Parfrey P.S., Griffiths S.M., Barrett B.J., et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both a prospective controlled study. N Engl J Med. 320:1989;143-149.
17. Cigarroa R.G., Lange R.A., Williams R.H., Hillis L.D. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 86:1989;649-652.
18. Chertow G.M., Christiansen C.L., Cleary P.D., Munro C., Lazarus J.M. Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. Arch Intern Med. 155:1995;1505-1511.
19. Zager R.A., Foerder C., Bredl C. The influence of mannitol on myoglobinuric acute renal failure functional, biochemical, and morphological assessments. J Am Soc Nephrol. 2:1991;848-855.
20. Bidani A.K., Fleischmann L.E., Churchill P., Becker-McKenna B. Natriuresis-induced protection in acute myohemoglobinuric renal failure without renal cortical renin content depletion in the rat. Nephron. 22:1978;529-537.
21. Weisberg L.S., Kurnik P.B., Kurnik B.R. Radiocontrast-induced nephropathy in humans role of renal vasoconstriction. Kidney Int. 41:1992;1408-1415.
22. Clark B.A., Kim D., Epstein F.H. Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans. Am J Kidney Dis. 30:1997;82-86.
23. Oken D.E. Hemodynamic basis for human acute renal failure (vasomotor nephropathy). Am J Med. 76:1984;702-710.